Publications by authors named "E S Bayram"
Background: We sought to characterize the cognitive profile among individuals with mild cognitive impairment with Lewy bodies (MCI-LB) to help guide future clinical criteria.
Methods: Systematic review and meta-analysis included MCI-LB studies with cognitive data from PubMed, Embase, Web of Science, and PsycINFO (January 1990 to March 2023). MCI-LB scores were compared to controls, MCI due to Alzheimer's disease (MCI-AD), and dementia with Lewy bodies (DLB) groups with random-effects models.
Background: The Montreal Cognitive assessment (MoCA) is a well-validated global cognitive screening instrument. Its validity in progressive supranuclear palsy (PSP) has not been assessed.
Objectives: To evaluate the MoCA as an outcome measure in PSP clinical trials.
Highly selective inhibitors of cyclin-dependent kinase 4 and 6 (CDK4/6is) have emerged as a standart of care for first- and second-line therapies in combination with endocrine therapy (ET) for HR+/HER2- metastatic breast cancer (MBC) patients. It has been reported that combination therapy is more effective than ET alone and is safe in elderly patients as well as young patients. Nevertheless, elderly and very old patients with HR+/HER2-MBC treated with CDK4/6 inhibitor (CDK4/6i) combinations are relatively underrepresented in randomized controlled trials.
View Article and Find Full Text PDFArticle Synopsis
- * Using various processing techniques, we discovered an ideal mix of extracts that boosted root growth in Arabidopsis by 25% and cut down on fertilizer needs by the same amount when applied to tomato plants.
- * Our analysis showed that this process not only enhances plant nutrient metabolism but also produces leftover biomass that could be used in a biorefinery for other products, improving cost-effectiveness.
Article Synopsis
- The study compared the effectiveness and safety of FOLFIRI combined with bevacizumab versus FOLFIRI combined with aflibercept in patients with RAS-mutant metastatic colon cancer who had previously received treatment.
- Results showed that patients receiving FOLFIRI with bevacizumab had a median overall survival (OS) of 14.1 months and progression-free survival (PFS) of 7.7 months, which were significantly better than those treated with aflibercept (OS: 11.2 months, PFS: 5.7 months).
- Additionally, the bevacizumab group experienced fewer severe side effects (50.9% in aflibercept group vs 25.